CA-ESRI
2.9.2021 15:44:07 CEST | Business Wire | Press release
When the United Nations adopted the Sustainable Development Goals (SDGs) as a global call to action to achieve a more sustainable future for all by 2030, many countries committed to the cause. Egypt, which launched its strategy in 2016, met the obstacle of geographic disparities due to the need for development in the upper region of the nation. To address this challenge, the Egyptian Ministry of Local Development and the World Bank launched the Upper Egypt Local Development Program (UELDP) a year later.
One vital step toward improving development in Upper Egypt—and part of UELDP—includes establishing a GIS infrastructure in the region. To achieve this, UELDP chose location intelligence world leader Esri to provide the region's new GIS unit with all the required hardware, software, data, and applications necessary for managing complex geospatial data.
"This is a strategically important project, which will play a vital role in driving sustainable, impactful urban planning and development to support communities in Upper Egypt," said Dr. Mohamed Misbah, director for the Middle East and Africa region at Khatib & Alami (K&A), an Esri Platinum partner.
The project will leverage a unified geodatabase and a map viewer to explore geostatistical information and generate reports, graphics, and thematic maps. It will also employ mobile applications for data collection that allow government staff to access data from the field. These services, in addition to operational dashboards, will provide a holistic view for policy makers.
Laying the foundation for asset management systems at the governorate (jurisdictional) level, Esri’s ArcGIS software helps integrate them with databases in relevant ministries and central government agencies. This enables these organizations to comprehensively display vast amounts of statistical and spatial information to support long-term planning and execution in line with UELDP's vision and future goals.
Further strengthening the governorates' capacities, GIS will enable local development data to be georeferenced to support decision-making. The implementation of this system was awarded to Esri partners ProSyLab and K&A.
"ProSyLab, as an Esri partner, adds to its achievements [by] participating in this national project," said Mahmoud Moursi, ProSyLab chairman. "The project aims to help the public sector, represented by the UELDP, in establishing a GIS infrastructure, which promotes the concept of data sharing, facilitating the decision-making process, and building capacity."
UELDP aims to localize sustainable development, create new job opportunities, improve the economy, and strengthen government capacity for quality infrastructure and service delivery in select governorates in Upper Egypt. It was piloted in the Qena and Sohag Governorates to address existing development gaps and has met with success, leading to national policy reforms, and even inspiring a scaled-up version of the program for Egypt's 2019 Decent Life initiative.
To learn more about how UELDP is using technology to enhance public services, visit ueldp.gov.eg .
About K&A
Khatib & Alami (K&A) is an international multidisciplinary consultancy composed of architects, engineers, planners, technologists and other project specialists. With 6,000 people in more than 30 locations, K&A has vast experience working at the forefront of fast changing urban environments, with a deep understanding of delivering complex major projects within agreed time frames and budgets.
Since launching its Geospatial Systems Integration division in 1988, K&A has become one of the leaders in its field, with a 200-strong team of GIS experts. K&A helps government and private sector clients make sense of the vast quantities of information and data available to them, providing insight, enabling better decision-making, creating efficiencies, and improving customer experiences. As an Esri Platinum partner, K&A continuously provides innovative smart solutions that address business challenges and exceed customers' expectations. For more information visit www.khatibalami.com .
About ProSyLab
ProSyLab is an information and communications technology company started in 1994. Since then, ProSyLab solutions have supported various customers in both the private and public sectors across Egypt as well as the Middle East.
ProSyLab (PSL) has a unique spirit and expertise which converts challenges into new success stories. With a portfolio of five companies in different market segments, ProSyLab has been supporting private sector and governmental enterprises across Egypt as well as the Middle East. PSL's innovative ideas and solutions are not merely our philosophy, but also our everyday reality. We remain dedicated to leading the world into a more prosperous and progressive future: by enhancing the world to become more diverse, more tolerant, and more just.
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005507/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom